Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.64 |
| ▸ | CDK9 | P50750 | 1/20 | 0.64 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.58 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | TAS2R38 | P59533 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CASP3 | P42574 | 1/20 | 0.54 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzene SCHEMBL28162617 | 0.78 | EPHX2 (0.70) | TP53TSHREPHX1SMN1; SMN2EPHX2 | |
| SCHEMBL57554 | 0.78 | SMN1; SMN2 (0.70) | TP53TSHREPHX1SMN1; SMN2EPHX2 | |
| Diphenylurea SCHEMBL133103 | 0.78 | SMN1; SMN2 (1.00) | TP53TSHREPHX1SMN1; SMN2EPHX2 | |
| SCHEMBL7634 | 0.78 | EPHX2 (0.70) | TP53TSHREPHX1SMN1; SMN2EPHX2 | |
| Benzene SCHEMBL28977956 | 0.78 | SMN1; SMN2 (0.70) | TP53TSHREPHX1SMN1; SMN2EPHX2 | |
| Iodide SCHEMBL5706290 | 0.76 | EPHX2 (0.67) | TP53TSHREPHX1SMN1; SMN2EPHX2 | |
| SCHEMBL54997 | 0.76 | EPHX2 (0.67) | TP53TSHREPHX1SMN1; SMN2EPHX2 | |
| SCHEMBL11353365 | 0.76 | EPHX2 (0.67) | TP53TSHREPHX1SMN1; SMN2EPHX2 | |
| Diphenylurea SCHEMBL3037927 | 0.76 | SMN1; SMN2 (0.94) | TP53TSHREPHX1SMN1; SMN2EPHX2 | |
| Water SCHEMBL9215020 | 0.76 | EPHX2 (0.67) | TP53TSHREPHX1SMN1; SMN2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194693-A1 | Aminoacetonitrile Derivatives and Their Use for Controlling Parasites on Warm-Blooded Animals | NOVARTIS AG (CH) | 2008-08-14 | — | — | US | claimed |
| EP-1758849-A1 | AMINOACETONITRILE DERIVATIVES AND THEIR USE FOR CONTROLLING PARASITES ON WARM-BLOODED ANIMALS | Novartis AG (CH) | 2007-03-07 | — | — | EP | claimed |
| WO-2005121075-A1 | AMINOACETONITRILE DERIVATIVES AND THEIR USE FOR CONTROLLING PARASITES ON WARM-BLOODED ANIMALS | NOVARTIS AG (CH) | 2005-12-22 | — | — | WO | claimed |
| US-7642379-B2 | Aminoacetonitrile derivatives and their use for controlling parasites on warm-blooded animals | NOVARTIS AG (CH) | 2010-01-05 | — | — | US | disclosed |
| US-20080194693-A1 | Aminoacetonitrile Derivatives and Their Use for Controlling Parasites on Warm-Blooded Animals | NOVARTIS AG (CH) | 2008-08-14 | — | — | US | disclosed |
| EP-1758849-A1 | AMINOACETONITRILE DERIVATIVES AND THEIR USE FOR CONTROLLING PARASITES ON WARM-BLOODED ANIMALS | Novartis AG (CH) | 2007-03-07 | — | — | EP | disclosed |
| US-20060088786-A1 | Rewritable optical information recording medium, recording and reproducing methods, as well as recording and reproducing apparatus | MITSUI CHEMICALS, INC. (JP) | 2006-04-27 | — | — | US | disclosed |
| WO-2005121075-A1 | AMINOACETONITRILE DERIVATIVES AND THEIR USE FOR CONTROLLING PARASITES ON WARM-BLOODED ANIMALS | NOVARTIS AG (CH) | 2005-12-22 | — | — | WO | disclosed |
| EP-1484191-A1 | REWRITABLE OPTICAL INFORMATION RECORDING MEDIUM AND RECORDING/REPRODUCING METHOD, RECORDING/REPRODUCING DEVICE | Sony Corporation (JP) | 2004-12-08 | — | — | EP | disclosed |
| EP-0550111-B1 | 2-Saccharinylmethyl heterocyclic carboxylates useful as proteolytic enzyme inhibitors and pharmaceutical compositions containing them | SANOFI SA (FR) | 1999-04-14 | — | — | EP | disclosed |
| US-5874432-A | Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof | SANOFI (FR) | 1999-02-23 | — | — | US | disclosed |
| US-5376653-A | A protease enzyme inhibitor for treating degenerative diseases , respiratory system disorders, rheumatoid arthritis and pancreatitis | STERLING WINTHROP INC. (US) | 1994-12-27 | — | — | US | disclosed |
| US-5371074-A | Use of saccharin derivatives as proteolytic enzyme inhibitors | STERLING WINTHROP INC. (US) | 1994-12-06 | — | — | US | disclosed |
| US-5236917-A | Respiratory system disorders, antiarthritic agents | STERLING WINTHROP INC. (US) | 1993-08-17 | — | — | US | disclosed |
| EP-0550112-A1 | 2-Saccharinylmethyl aryl and aryloxy acetates useful as proteolytic enzyme inhibitors and pharmaceutical compositions contaning them | STERLING WINTHROP INC. (US) | 1993-07-07 | — | — | EP | disclosed |
| EP-0550111-A1 | 2-Saccharinylmethyl heterocyclic carboxylates useful as proteolytic enzyme inhibitors and pharmaceutical compositions containing them | STERLING WINTHROP INC. (US) | 1993-07-07 | — | — | EP | disclosed |
| EP-0542372-A1 | 2-Substituted saccharin derivative proteolytic enzyme inhibitors | STERLING WINTHROP INC. (US) | 1993-05-19 | — | — | EP | disclosed |
| EP-0471756-A4 | SACCHARIN DERIVATIVES USEFUL AS PROTEOLYTIC ENZYME INHIBITORS AND PREPARATION THEREOF | — | 1992-04-08 | — | — | EP | disclosed |
| EP-0471756-A1 | SACCHARIN DERIVATIVES USEFUL AS PROTEOLYTIC ENZYME INHIBITORS AND PREPARATION THEREOF. | STERLING WINTHROP INC (US) | 1992-02-26 | — | — | EP | disclosed |
| WO-1990013549-A1 | SACCHARIN DERIVATIVES USEFUL AS PROTEOLYTIC ENZYME INHIBITORS AND PREPARATION THEREOF | STERLING WINTHROP INC. (US) | 1990-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194693-A1 | Aminoacetonitrile Derivatives and Their Use for Controlling Parasites on Warm-Blooded Animals | MB, ACHE, ADORA2B | TP53 3970/4885TSHR 3029/4885EPHX1 671/4885 |
| US-20060088786-A1 | Rewritable optical information recording medium, recording and reproducing methods, as well as recording and reproducing apparatus | ALPG, TRPC6, GNRHR | TP53 4662/4885TSHR 1237/4885EPHX1 2778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.